All Stories

  1. Modification of a salmonid alphavirus replicon vector for enhanced expression of heterologous antigens
  2. Self-replicating alphavirus RNA vaccines
  3. Prime-Boost Immunization Strategies against Chikungunya Virus
  4. Kinetic and Phenotypic Analysis of CD8+ T Cell Responses after Priming with Alphavirus Replicons and Homologous or Heterologous Booster Immunizations
  5. A 6K-Deletion Variant of Salmonid Alphavirus Is Non-Viable but Can Be Rescued through RNA Recombination
  6. A Novel Poxvirus-Based Vaccine, MVA-CHIKV, Is Highly Immunogenic and Protects Mice against Chikungunya Infection
  7. Intradermal Electroporation of RNA
  8. Novel Attenuated Chikungunya Vaccine Candidates Elicit Protective Immunity in C57BL/6 mice
  9. Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout
  10. The Adjuvant Activity of Alphavirus Replicons Is Enhanced by Incorporating the Microbial Molecule Flagellin into the Replicon
  11. Optimizing delivery of HIV-1 conserved region-derived immunogen for induction of T and B cell responses in rhesus macaques
  12. Host Gene Expression Signatures Discriminate between Ferrets Infected with Genetically Similar H1N1 Strains
  13. De-Novo Transcriptome Sequencing of a Normalized cDNA Pool from Influenza Infected Ferrets
  14. Differential Impact of Interferon Regulatory Factor 7 in Initiation of the Type I Interferon Response in the Lymphocytic Choriomeningitis Virus-Infected Central Nervous System versus the Periphery
  15. Superior Induction of T Cell Responses to Conserved HIV-1 Regions by Electroporated Alphavirus Replicon DNA Compared to That with Conventional Plasmid DNA Vaccine
  16. Intradermal Electroporation of Naked Replicon RNA Elicits Strong Immune Responses
  17. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
  18. Protective Efficacy of Serially Up-Ranked Subdominant CD8+ T Cell Epitopes against Virus Challenges
  19. Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines
  20. Long peptides induce polyfunctional T cells against conserved regions of HIV‐1 with superior breadth to single‐gene vaccines in macaques
  21. Preclinical Evaluation of the Immunogenicity of C-Type HIV-1-Based DNA and NYVAC Vaccines in the Balb/C Mouse Model
  22. P17-05. Dealing with HIV-1 diversity
  23. Comparison of Human and Rhesus Macaque T-Cell Responses Elicited by Boosting with NYVAC Encoding Human Immunodeficiency Virus Type 1 Clade C Immunogens
  24. EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium
  25. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
  26. Increased human immunodeficiency virus type 1 Env expression and antibody induction using an enhanced alphavirus vector
  27. Semliki Forest Virus Nonstructural Protein 2 Is Involved in Suppression of the Type I Interferon Response
  28. Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor
  29. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B
  30. Viral vectors for malaria vaccine development
  31. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C
  32. RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates
  33. Humoral Responses against Coimmunized Protein Antigen but Not against Alphavirus-Encoded Antigens Require Alpha/Beta Interferon Signaling
  34. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles
  35. Modulation of Vaccine‐Induced Immune Responses to Hepatitis C Virus in Rhesus Macaques by Altering Priming before Adenovirus Boosting
  36. Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus
  37. Early Alpha/Beta Interferon Production by Myeloid Dendritic Cells in Response to UV-Inactivated Virus Requires Viral Entry and Interferon Regulatory Factor 3 but Not MyD88
  38. Reversible Acid-Induced Inactivation of the Membrane Fusion Protein of Semliki Forest Virus
  39. MyD88 Expression Is Required for Efficient Cross-Presentation of Viral Antigens from Infected Cells
  40. Toll-like receptor 3 promotes cross-priming to virus-infected cells
  41. T‐cell‐mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge
  42. DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model
  43. Semliki Forest virus produced in the absence of the 6K protein has an altered spike structure as revealed by decreased membrane fusion capacity
  44. Immunization with PfEMP1-DBL1α generates antibodies that disrupt rosettes and protect against the sequestration of Plasmodium falciparum-infected erythrocytes
  45. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene
  46. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo
  47. Vaccination with Recombinant Alphavirus or Immune-Stimulating Complex Antigen Against Respiratory Syncytial Virus
  48. Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols
  49. Foreword
  50. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response
  51. A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model
  52. Comparative Immunization Study Using RNA and DNA Constructs Encoding a Part of the Plasmodium falciparum Antigen Pf332
  53. M-X-I Motif of Semliki Forest Virus Capsid Protein Affects Nucleocapsid Assembly
  54. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara
  55. Self‐Replicative RNA Vaccines Elicit Protection against Influenza A Virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus
  56. Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems
  57. Use of Conventional or Replicating Nucleic Acid-Based Vaccines and Recombinant Semliki Forest Virus-Derived Particles for the Induction of Immune Responses Against Hepatitis C Virus Core and E2 Antigens
  58. A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens
  59. Alphavirus vectors: from protein production to gene therapy
  60. Alphavirus Vectors: Highly Efficient Systems for Transient Gene Expression
  61. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene
  62. An anti‐HIV strategy combining chemotherapy and therapeutic vaccination
  63. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice
  64. Enhancing immune responses using suicidal DNA vaccines
  65. Role of the C-terminal tryptophan residue for the structure-function of the alphavirus capsid protein
  66. Outcome of Immunization of Cynomolgus Monkeys with Recombinant Semliki Forest Virus Encoding Human Immunodeficiency Virus Type 1 Envelope Protein and Challenge with a High Dose of SHIV-4 Virus
  67. Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells
  68. Preface
  69. Alphavirus expression vectors and their use as recombinant vaccines: a minireview
  70. Aromatic interactions define the binding of the alphavirus spike to its nucleocapsid
  71. Alphaviruses as vectors for gene delivery
  72. Manipulation of the Semliki Forest virus genome and its potential for vaccine construction
  73. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.
  74. Recombinant Self-Replicating RNA Vaccines
  75. High-Level Expression of G Protein-Coupled Receptors with the Aid of the Semliki Forest Virus Expression System
  76. The Tax transactivation protein of human T-cell leukemia virus type I colocalizes with NF-κB proteins in nuclear bodies
  77. Self-replicating Semliki Forest virus RNA as recombinant vaccine
  78. Alphavirus expression systems
  79. High‐level Expression of the Human Neurokinin‐1 Receptor in Mammalian Cell Lines using the Semliki Forest Virus Expression System
  80. A single amino acid change in the E2 spike protein of a virulent strain of Semliki Forest virus attenuates pathogenicity
  81. Chapter 2 Expression of Exogenous Proteins in Mammalian Cells with the Semliki Forest Virus Vector
  82. Assembly and entry mechamisms of Semliki Forest virus
  83. Plasminogen‐activator inhibitor type 2 (PAI‐2) is a spontaneously polymerising SERPIN
  84. Expression of HIV-1 Envelope Glycoproteins by Semliki Forest Virus Vectors
  85. Semliki Forest Virus Expression System: Production of Conditionally Infectious Recombinant Particles
  86. Overview: Virally Based Transient Expression Systems
  87. A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon
  88. Structure and expression of the ompB operon, the regulatory locus for the outer membrane porin regulon in Salmonella typhimurium LT-2
  89. Nucleotide sequence of the melA gene, Coding for α-galactosidase in Escherichia coli K-12
  90. The EnvZ protein of Salmonella typhimurium LT-2 and Escherichia coli K-12 is located in the cytoplasmic membrane
  91. In vivo transfer of chromosomal mutations onto multicopy plasmids by transduction with bacteriophage P1
  92. Live Viral Vectors: Semliki Forest Virus
  93. Delivery and Expression of Heterologous Genes in Mammalian Cells Using Self-Replicating Alphavirus Vectors
  94. The SFV Gene Expression System